Related Experiment Videos
Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy
H Ahman1, H Käyhty, H Lehtonen
1National Public Health Institute, Helsinki, Finland. heidi.ahman@ktl.fi
Insights
A new pneumococcal conjugate vaccine (PncD) shows promise for infant immunization. It is immunogenic and establishes immunological memory, offering a potential new strategy against pneumococcal diseases.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Pneumococcal polysaccharide vaccines are ineffective for common infant infections.
- Rising antimicrobial resistance necessitates novel prophylactic strategies against pneumococcal diseases.
Purpose of the Study:
- To evaluate the immunogenicity and efficacy of a novel pneumococcal conjugate vaccine (PncD) in infants.
- To determine optimal dosing and immune memory induction by PncD.
Main Methods:
- Infants received PncD (serotypes 6B, 14, 19F, 23F conjugated to diphtheria toxoid) at 2, 4, and 6 months with varying doses (1, 3, or 10 µg).
- A booster dose was administered at 14 months.
- Antibody concentrations were measured using enzyme immunoassay.
Main Results:
- Higher PncD doses yielded stronger primary responses, while lower doses produced greater booster responses.
- Both polysaccharide and conjugate vaccines induced comparable booster responses.
- Antibody levels at 24 and 36 months were similar between infants immunized in infancy and those immunized only at 14 months.
Conclusions:
- The PncD conjugate vaccine is immunogenic in infants.
- PncD vaccination effectively induces immunological memory, suggesting long-term protection potential.
Background:
Pneumococcal polysaccharide vaccines are not protective against the most common pneumococcal infections in infancy. The importance of pneumococcal diseases and emerging antimicrobial resistance emphasize the need for prophylaxis.
Methods:
Pneumococcal conjugate vaccine, containing capsular polysaccharides from serotypes 6B, 14, 19F and 23F conjugated to diphtheria toxoid (PncD), was given to 75 infants at 2, 4 and 6 months of age. Three dosages (1, 3 or 10 microg of each) were used. A placebo group of 49 infants received physiologic saline. Children were given a booster dose of either polysaccharide or conjugate vaccine at 14 months of age; the placebo group received conjugate vaccine. Antibody concentrations were determined with an enzyme immunoassay.
Results:
The highest dose induced the strongest response after primary immunization, but booster response was greatest in the group primed with the lowest dose. Polysaccharide and conjugate vaccines induced booster responses of the same magnitude. At 24 and 36 months of age the antibody concentrations were similar in children who had received the PncD in infancy and in children immunized at 14 months of age only.
Conclusions:
The PncD conjugate vaccine is immunogenic and able to induce immunologic memory.